Massive Bio launches personalized clinical research matching technology to reach 100,000 cancer patients.
NEW YORK, USA, July 29, 2022 /EINPresswire.com/ — The use of artificial intelligence (AI) technology has revolutionized a variety of fields, including the healthcare sector. Health and manageability of human life are of vital importance to technology, which is developing at a rapid pace. The situation is even more complicated if the problem is not yet resolved, even in the health sector, as cancer. Existing treatment methods are ineffective in the fight against cancer, so new treatment methods will be the only solution. Moreover, since participating in clinical trials to achieve these treatments is a difficult task, companies wishing to serve in this field must swim against the ocean. Massive organicfounded to “wipe cancer off the map”, succeeded in this mission thanks to the artificial intelligence technology it developed.
Molecular profiling system
The company provides cancer patients with personalized services at the right time and at the right scale by performing comprehensive molecular profiling through next-generation sequencing (NGS) assays. Using Massive Bio’s artificial intelligence algorithms, patients enter their cancer data, and Massive Bio’s algorithms quickly identify the best treatment from existing clinical studies. Due to the sensitive nature of this process, the entire process is kept confidential.
Complies with HIPAA, GDPR and EU clinical trial regulations
Patient privacy is of utmost importance to Massive Bio. No medical information is disclosed. Our algorithms filter patient information after they send us their reports, and all personal information is encrypted. Then CTMS (Clinical Trial Matching System) starts matching our patient data with the clinical trials.
Data collection is carried out with the knowledge of the patients. All studies comply with HIPAA (Health Insurance Portability and Accountability Act), GDPR (General Data Protection Regulation) and European clinical trial regulations.
NLP and computer vision technology
Massive Bio matches clinical research data from halfway around the world with patient data using end-to-end artificial intelligence algorithms, including NLP (neuro-linguistic programming) and computer vision. computer. Thanks to the end-to-end service of Massive Bio AI technologypatients can choose the most suitable treatment method within minutes.
These characteristics are unique to Massive Bio. Providing outstanding technology services and a big data platform for the healthcare industry, it solves bottlenecks in clinical trials worldwide. The program aims to improve the lives of cancer patients. This company is also at the service of hospital networks and pharmaceutical laboratories. Currently, Massive Bio has reached 60,000 cancer patients in 12 countries. It aims to quickly spread to wider geographical areas and eradicate this disease from the map by finding the most suitable treatment methods.
With technology, big data and services, we will wake up one morning to learn that “cancer is buried in the hidden pages of history”. The perfect harmony of this trio is the basis of the extremely determined, passionate and hardworking principle of Massive Bio.
About Massive Bio
Massive Bio, a New York-based company founded in 2015, offers clinical trials to cancer patients worldwide, regardless of location or finances. As a provider of technology-enabled clinical trial services and big data platforms, Massive Bio solves bottlenecks in the healthcare industry. One of Massive Bio’s main objectives is to improve the quality of life of cancer patients by serving pharmaceutical companies, contract research organizations (CROs) and hospital networks. It provides corporate clients with oncology-specific data-driven patient recruitment, site selection and AI-based trial screening services. The company provides personalized service to cancer patients at the right time, at scale, by extracting genetic information from next-generation sequencing (next-generation sequencing) reports via AI and matching patients to the most related. Cancer patients, regardless of where they live and their economic circumstances, can participate in clinical studies through Massive Bio, the only company that brings them together. Technology, big data and service can all be combined in hours with this company.
The American National Cancer Institute (NCI) has awarded Massive Bio an SBIR contract to develop and characterize its Deep Learning Clinical Trial Matching System (DLCTMS). Massive Bio is the official matching partner for all NCI-funded clinical trials. In addition, the company participates in the Integrated Trial Matching for Cancer Patients and Providers project led by MITER and the American Cancer Society Cancer Action Network. Investments have totaled more than $18 million since Massive Bio’s inception. The company has more than 1000 clinical research centers worldwide, partnerships with 26 pharmaceutical companies and 74 employees. In 2021, Massive Bio, which has already associated more than 60,000 patients with clinical trials, plans to reach 100,000 cancer patients in 19 countries through the “100K Cancer Clinical Trial Singularity Program”.
You can reach Massive Bio via [email protected], Twitter, LinkedIn and Facebook.
Email: [email protected]